Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Yttrium-90 Radioembolization in advanced HCC
NCT04124991Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by Seoul National University Hospital. Started Jun 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04124991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124991.